Diabetic ketoacidosis (DKA) is a serious complication of type 1 diabetes mellitus, accounting for around 6% of cases. It can also occur in rare cases of extreme stress in patients with type 2 diabetes mellitus. However, mortality rates have decreased from 8% to under 1% in the past 20 years. DKA is caused by uncontrolled lipolysis, resulting in an excess of free fatty acids that are ultimately converted to ketone bodies. The most common precipitating factors of DKA are infection, missed insulin doses, and myocardial infarction. Symptoms include abdominal pain, polyuria, polydipsia, dehydration, Kussmaul respiration, and acetone-smelling breath. Diagnostic criteria include glucose levels above 13.8 mmol/l, pH below 7.30, serum bicarbonate below 18 mmol/l, anion gap above 10, and ketonaemia.

Management of DKA involves fluid replacement, insulin, and correction of electrolyte disturbance. Most patients with DKA are depleted around 5-8 litres, and isotonic saline is used initially, even if the patient is severely acidotic. Insulin is administered through an intravenous infusion, and correction of electrolyte disturbance is necessary. Long-acting insulin should be continued, while short-acting insulin should be stopped. DKA resolution is defined as pH above 7.3, blood ketones below 0.6 mmol/L, and bicarbonate above 15.0mmol/L. Complications may occur from DKA itself or the treatment, such as gastric stasis, thromboembolism, arrhythmias, acute respiratory distress syndrome, acute kidney injury, and cerebral oedema. Children and young adults are particularly vulnerable to cerebral oedema following fluid resuscitation in DKA and often need 1:1 nursing to monitor neuro-observations.

Genetics and Types of Colorectal Cancer

Colorectal cancer is a type of cancer that affects the colon and rectum. There are three main types of colorectal cancer: sporadic, hereditary non-polyposis colorectal carcinoma (HNPCC), and familial adenomatous polyposis (FAP). Sporadic colon cancer is the most common type, accounting for 95% of cases. It is believed to be caused by a series of genetic mutations, including allelic loss of the APC gene, activation of the K-ras oncogene, and deletion of p53 and DCC tumour suppressor genes.

HNPCC, also known as Lynch syndrome, is an autosomal dominant condition that accounts for 5% of cases. It is the most common form of inherited colon cancer and is caused by mutations in genes involved in DNA mismatch repair, leading to microsatellite instability. The most commonly affected genes are MSH2 and MLH1. Patients with HNPCC are also at a higher risk of developing other cancers, such as endometrial cancer.

FAP is a rare autosomal dominant condition that accounts for less than 1% of cases. It is caused by a mutation in the adenomatous polyposis coli gene (APC), which leads to the formation of hundreds of polyps by the age of 30-40 years. Patients with FAP inevitably develop carcinoma and are also at risk of duodenal tumors. A variant of FAP called Gardner’s syndrome can also feature osteomas of the skull and mandible, retinal pigmentation, thyroid carcinoma, and epidermoid cysts on the skin.

In conclusion, understanding the genetics behind colorectal cancer is important for diagnosis and treatment. While sporadic colon cancer is the most common type, HNPCC and FAP are inherited conditions that require genetic testing and surveillance for early detection and prevention.

Understanding Wernicke’s Encephalopathy

Wernicke’s encephalopathy is a condition that affects the brain and is caused by a deficiency in thiamine. This condition is commonly seen in individuals who abuse alcohol, but it can also be caused by persistent vomiting, stomach cancer, or dietary deficiencies. The classic triad of symptoms associated with Wernicke’s encephalopathy includes oculomotor dysfunction, gait ataxia, and encephalopathy. Other symptoms may include peripheral sensory neuropathy and confusion.

When left untreated, Wernicke’s encephalopathy can lead to the development of Korsakoff’s syndrome. This condition is characterized by antero- and retrograde amnesia and confabulation in addition to the symptoms associated with Wernicke’s encephalopathy.

To diagnose Wernicke’s encephalopathy, doctors may perform a variety of tests, including a decreased red cell transketolase test and an MRI. Treatment for this condition involves urgent replacement of thiamine. With prompt treatment, individuals with Wernicke’s encephalopathy can recover fully.

Controlled hyperventilation can be employed for patients with elevated ICP by increasing CO2 expiration. This leads to constriction of cerebral arteries due to low blood CO2 levels. As a result, blood flow decreases, reducing the volume inside the cranium and ultimately lowering intracranial pressure. Therefore, the other options are incorrect.

Understanding Raised Intracranial Pressure

As the brain and ventricles are enclosed by a rigid skull, any additional volume such as haematoma, tumour, or excessive cerebrospinal fluid (CSF) can lead to a rise in intracranial pressure (ICP). In adults, the normal ICP is between 7-15 mmHg in the supine position. The net pressure gradient causing cerebral blood flow to the brain is known as cerebral perfusion pressure (CPP), which can be calculated by subtracting ICP from mean arterial pressure.

Raised intracranial pressure can be caused by various factors such as idiopathic intracranial hypertension, traumatic head injuries, infections, meningitis, tumours, and hydrocephalus. Its symptoms include headache, vomiting, reduced levels of consciousness, papilloedema, and Cushing’s triad, which is characterized by widening pulse pressure, bradycardia, and irregular breathing.

To investigate the underlying cause, neuroimaging such as CT or MRI is key. Invasive ICP monitoring can also be done by placing a catheter into the lateral ventricles of the brain to monitor the pressure, collect CSF samples, and drain small amounts of CSF to reduce the pressure. A cut-off of >20 mmHg is often used to determine if further treatment is needed to reduce the ICP.

Management of raised intracranial pressure involves investigating and treating the underlying cause, head elevation to 30º, IV mannitol as an osmotic diuretic, controlled hyperventilation to reduce pCO2 and vasoconstriction of the cerebral arteries, and removal of CSF through techniques such as drain from intraventricular monitor, repeated lumbar puncture, or ventriculoperitoneal shunt for hydrocephalus.

The management of vitamin B12 deficiency typically involves intramuscular replacement of B12, with a loading regimen followed by injections every 2-3 months. Patients with this deficiency may experience symptoms such as fatigue, poor concentration, and pallor, and blood tests may confirm the presence of anemia, low B12, low folate, and hypersegmented polymorphs on a blood film. In some cases, patients may also experience thrombocytopenia due to the role of B12 as a co-factor in bone marrow cell synthesis. While patients with neurological symptoms or who are pregnant should be urgently referred, this patient does not meet those criteria. Referral to haematology may be necessary if the patient has a suspected blood disorder or malignancy, fails to respond to treatment, or has a persistently high mean cell volume. Referral to gastroenterology may be necessary if the patient has a malabsorption syndrome, gastric cancer, or pernicious anemia with gastrointestinal symptoms. Intramuscular replacement of B12 is preferred over oral replacement, as per NICE guidelines, and should always be administered prior to folate replacement to avoid spinal cord degeneration.

Understanding Pernicious Anaemia

Pernicious anaemia is a condition that results in vitamin B12 deficiency due to an autoimmune disorder affecting the gastric mucosa. The term pernicious means causing harm in a gradual or subtle way, and this is reflected in the often subtle symptoms and delayed diagnosis of the condition. While pernicious anaemia is the most common cause of vitamin B12 deficiency, other causes include atrophic gastritis, gastrectomy, and malnutrition.

The pathophysiology of pernicious anaemia involves antibodies to intrinsic factor and/or gastric parietal cells. These antibodies can bind to intrinsic factor, blocking the vitamin B12 binding site, or reduce acid production and cause atrophic gastritis. This leads to reduced intrinsic factor production and reduced vitamin B12 absorption, which can result in megaloblastic anaemia and neuropathy.

Risk factors for pernicious anaemia include being female, middle to old age, and having other autoimmune disorders such as thyroid disease, type 1 diabetes mellitus, Addison’s, rheumatoid arthritis, and vitiligo. It is also more common in individuals with blood group A.

Symptoms of pernicious anaemia include anaemia features such as lethargy, pallor, and dyspnoea, as well as neurological features such as peripheral neuropathy and subacute combined degeneration of the spinal cord. Neuropsychiatric features such as memory loss, poor concentration, confusion, depression, and irritability may also be present, along with mild jaundice and glossitis.

Diagnosis of pernicious anaemia involves a full blood count, vitamin B12 and folate levels, and testing for antibodies such as anti intrinsic factor antibodies and anti gastric parietal cell antibodies. Treatment involves vitamin B12 replacement, usually given intramuscularly, and folic acid supplementation may also be required. Complications of pernicious anaemia include an increased risk of gastric cancer.

Haemodialysis, sickle-cell anaemia, GP6D deficiency, and hereditary spherocytosis are conditions that can cause premature red blood cell death, leading to invalid results when measuring HbA1c levels. HbA1c is a form of haemoglobin that indicates the three-month average blood sugar level. Haemodialysis, in particular, can result in lower-than-expected HbA1c levels due to its reduction of red blood cell lifespan. Amoxicillin and citalopram are not known to affect HbA1c levels, while drugs like trimethoprim-sulfamethoxazole can increase erythrocyte destruction and cause inappropriately low HbA1c levels. Iron-deficiency anaemia, on the other hand, can cause higher-than-expected HbA1c levels, making it crucial to treat the condition to accurately track diabetic control.

Understanding Glycosylated Haemoglobin (HbA1c) in Diabetes Mellitus

Glycosylated haemoglobin (HbA1c) is a commonly used measure of long-term blood sugar control in diabetes mellitus. It is produced when glucose attaches to haemoglobin in the blood at a rate proportional to the glucose concentration. The level of HbA1c is influenced by the lifespan of red blood cells and the average blood glucose concentration. However, certain conditions such as sickle-cell anaemia, GP6D deficiency, and haemodialysis can interfere with accurate interpretation of HbA1c levels.

HbA1c is believed to reflect the blood glucose levels over the past 2-4 weeks, although it is generally thought to represent the previous 3 months. It is recommended that HbA1c be checked every 3-6 months until stable, then every 6 months. The Diabetes Control and Complications Trial (DCCT) has studied the complex relationship between HbA1c and average blood glucose. The International Federation of Clinical Chemistry (IFCC) has developed a new standardised method for reporting HbA1c in mmol per mol of haemoglobin without glucose attached.

The table above shows the relationship between HbA1c, average plasma glucose, and IFCC-HbA1c. By using this table, we can calculate the average plasma glucose level by multiplying HbA1c by 2 and subtracting 4.5. Understanding HbA1c is crucial in managing diabetes mellitus and achieving optimal blood sugar control.

BTS/SIGN Guidelines on Asthma Diagnosis and Management

Guidelines from BTS/SIGN provide recommendations on how to diagnose and manage asthma. Symptoms such as wheezing, breathlessness, chest tightness, or cough, especially if they worsen at night or in the early morning, after exercise, allergy exposure, or cold air, are indicative of asthma. Other factors that support the diagnosis include a family history of atopy or asthma, personal history of atopy, widespread wheezing, low FEV1 or PEFR. However, symptoms such as dizziness, light-headedness, voice disturbance, and chronic cough without wheezing do not suggest asthma. Additionally, there is no evidence that symptoms corresponding to a cold indicate an underlying diagnosis of asthma. These guidelines aim to help healthcare professionals accurately diagnose and manage asthma in patients.

The most common organism associated with bronchiectasis is Haemophilus influenzae, making it the correct answer for an acute exacerbation of this condition. While Klebsiella pneumonia is also a possibility, it is less frequently seen and typically associated with pneumonia in patients with alcohol dependence. Pseudomonas aeruginosa is an incorrect answer, as it is more commonly found in patients with cystic fibrosis than bronchiectasis. Staphylococcus aureus is also less commonly isolated in bronchiectasis, and is more commonly associated with other infective conditions such as infective endocarditis and skin infections, as well as being a secondary bacterial cause of pneumonia following influenzae.

Managing Bronchiectasis

Bronchiectasis is a condition where the airways become permanently dilated due to chronic inflammation or infection. Before starting treatment, it is important to identify any underlying causes that can be treated, such as immune deficiency. The management of bronchiectasis includes physical training, such as inspiratory muscle training, which has been shown to be effective for patients without cystic fibrosis. Postural drainage, antibiotics for exacerbations, and long-term rotating antibiotics for severe cases are also recommended. Bronchodilators may be used in selected cases, and immunizations are important to prevent infections. Surgery may be considered for localized disease. The most common organisms isolated from patients with bronchiectasis include Haemophilus influenzae, Pseudomonas aeruginosa, Klebsiella spp., and Streptococcus pneumoniae.

Spacing:

Bronchiectasis is a condition where the airways become permanently dilated due to chronic inflammation or infection. Before starting treatment, it is important to identify any underlying causes that can be treated, such as immune deficiency.

The management of bronchiectasis includes physical training, such as inspiratory muscle training, which has been shown to be effective for patients without cystic fibrosis. Postural drainage, antibiotics for exacerbations, and long-term rotating antibiotics for severe cases are also recommended. Bronchodilators may be used in selected cases, and immunizations are important to prevent infections. Surgery may be considered for localized disease.

The most common organisms isolated from patients with bronchiectasis include Haemophilus influenzae, Pseudomonas aeruginosa, Klebsiella spp., and Streptococcus pneumoniae.

Myasthenia gravis is an autoimmune disorder that results in insufficient functioning acetylcholine receptors. It is more common in women and is characterized by muscle fatigability, extraocular muscle weakness, proximal muscle weakness, ptosis, and dysphagia. Thymomas are present in 15% of cases, and autoimmune disorders are also associated with the disease. Diagnosis is made through single fibre electromyography and CT thorax to exclude thymoma. Management includes long-acting acetylcholinesterase inhibitors, immunosuppression, and thymectomy. Plasmapheresis and intravenous immunoglobulins are used to manage myasthenic crisis. Antibodies to acetylcholine receptors are seen in 85-90% of cases.

Beta-blockers are frequently prescribed for hypertension treatment, but they can lead to cold extremities as a side effect. Thiazide diuretics like bendroflumethiazide commonly cause constipation, diarrhea, dizziness, and dry mouth. Angiotensin receptor blockers such as candesartan and losartan do not typically result in cold peripheries.

Beta-blockers are a class of drugs that are primarily used to manage cardiovascular disorders. They have a wide range of indications, including angina, post-myocardial infarction, heart failure, arrhythmias, hypertension, thyrotoxicosis, migraine prophylaxis, and anxiety. Beta-blockers were previously avoided in heart failure, but recent evidence suggests that certain beta-blockers can improve both symptoms and mortality. They have also replaced digoxin as the rate-control drug of choice in atrial fibrillation. However, their role in reducing stroke and myocardial infarction has diminished in recent years due to a lack of evidence. Examples of beta-blockers include atenolol and propranolol, which was one of the first beta-blockers to be developed and is lipid soluble, allowing it to cross the blood-brain barrier.

Like all drugs, beta-blockers have side-effects, including bronchospasm, cold peripheries, fatigue, sleep disturbances (including nightmares), and erectile dysfunction. They are contraindicated in uncontrolled heart failure, asthma, sick sinus syndrome, and concurrent use with verapamil, which may precipitate severe bradycardia.